Immuron

Analyst Reports

Corporate Governance

Corporate Directory

Corporate

Capital Structure & Register

Annual Reports

Investor Presentations

NASDAQ

Investors

Company Media

Announcements

The Digest

Why Immuron?

Home

Plus Jakarta Sans

Click here to read full article

Investors responded strongly—doubling Immuron’s share price—following preliminary in vitro results showing its traveller’s diarrhea formulation IMM‑124E (Travelan®) exhibited neutralizing activity against SARS‑CoV‑2, suggesting potential antiviral properties in the gastrointestinal tract; the company has since filed a provisional patent while noting that further studies are needed to identify the exact inhibitory components responsible.

The Market Online: Could Immuron’s (ASX:IMC) traveller’s diarrhoea treatment be used to fight COVID-19?